{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T20:18:05Z","timestamp":1793823485683,"version":"4.6.1"},"reference-count":72,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:00:00Z","timestamp":1787097600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Cancer incidence and mortality have been increasing both globally and in Greece. The aim of this study was to quantify the health benefits and budget impact of including anti-PD-(L)1\u2019s in three early-stage cancer indications, adjuvant melanoma stage IIB\/C and III, adjuvant renal cell carcinoma, and perioperative triple-negative breast cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A Markov model approach was used to predict clinical outcomes and costs throughout the average patient pathway over a 10-year time horizon. The model includes two scenarios: (1) using anti-PD-(L)1\u2019s for patients with early-stage and metastatic disease (ESD scenario) versus (2) treatment with the previous standard of care in the early-stage and anti-PD-(L)1\u2019s only in the metastatic disease setting (reference scenario). Estimated outcomes include life-years (LYs), quality-adjusted life-years (QALYs), events or recurrences, productive LYs lost for patients and caregivers, active treatments administered for metastatic disease, deaths, and costs. The model inputs included efficacy data from clinical trials, Greek data on market shares, projected eligible patients, and the respective costs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Results indicate the following in the ESD scenario: a reduction of 1,722 (25%) recurrences, 881 (24%) deaths, an increase of 5,555 (11%) LYs without recurrence, an increase of productive LYs by 901 (16%) and 2,363 QALYs gained (4%), and a decrease of 1,782 (27%) in active treatments for the metastatic disease setting. The average incremental budget impact per patient per annum was \u20ac31,853 throughout the 10-year time horizon of the model from 2023 to 2032.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Results indicate that adjuvant\/perioperative treatments could provide a significant benefit to patients with cancer, with a manageable additional cost for the healthcare system. The estimations of the model demonstrate a strong call to action for policymakers to enhance access to innovative treatments, since benefits arise for patients, their caregivers, and society as a whole through increased productivity gains.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1814460","type":"journal-article","created":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T09:50:55Z","timestamp":1787133055000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Assessing the health outcomes, productivity gains, and budget impact of anti-PD-(L)1\u2019s in the early stages of cancer treatment in Greece"],"prefix":"10.3389","volume":"16","author":[{"given":"Nikolaos Themistoklis","family":"Yfantopoulos","sequence":"first","affiliation":[{"name":"MSD Greece","place":["Athens, Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panagiota","family":"Naoum","sequence":"additional","affiliation":[{"name":"Institute for Health Economics","place":["Athens, Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasios","family":"Skroumpelos","sequence":"additional","affiliation":[{"name":"MSD Greece","place":["Athens, Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonis","family":"Karokis","sequence":"additional","affiliation":[{"name":"MSD Greece","place":["Athens, Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Demet","family":"S\u00f6nmez","sequence":"additional","affiliation":[{"name":"Value & Implementation Global Medical and Scientific Affairs, MSD","place":["Stockholm, Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"Aguiar-Iba\u00f1ez","sequence":"additional","affiliation":[{"name":"Value & Implementation Outcomes Research, Merck & Co., Inc.","place":["Rahway, NJ, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivek","family":"Khurana","sequence":"additional","affiliation":[{"name":"Value & Implementation Outcomes Research, MSD Sharp & Dohme GmbH","place":["Munich, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasios","family":"Boutis","sequence":"additional","affiliation":[{"name":"3rd Department of Medical Oncology, Theagenio Cancer Hospital","place":["Thessaloniki, Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michail","family":"Liontos","sequence":"additional","affiliation":[{"name":"Oncology Unit, Department of Clinical Therapeutics, Medical School and National and Kapodistrian University of Athens, Alexandra Hospital","place":["Athens, Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zacharenia","family":"Saridaki","sequence":"additional","affiliation":[{"name":"1st Oncological Clinic, Metropolitan Hospital, Athens, Greece and Oncology Department, \u201cAsklepios DIAGNOSIS\u201d","place":["Heraklion, Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kostas","family":"Athanasakis","sequence":"additional","affiliation":[{"name":"Department of Public Health Policy, University of West Attica","place":["Athens, Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,19]]},"reference":[{"key":"B1","volume-title":"Global Cancer Burden Growing, Amidst Mounting Need for Services","year":"2024"},{"key":"B2","volume-title":"A Cancer Plan for Europe : Europe\u2019s Beating Cancer Plan","year":"2022"},{"key":"B3","volume-title":"Greece Cancer Fact Sheet","year":"2020"},{"key":"B4","volume-title":"Estimated Number of New Cases From 2020 to 2040, Both Sexes, Age [0-85+]","year":"2023"},{"key":"B5","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.vhri.2020.05.007","article-title":"Can we incorporate societal values in resource allocation decisions among disease categories? An empirical approach","volume":"25","author":"Athanasakis","year":"2021","journal-title":"Value Health Reg Issues"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.epi-23-1018","article-title":"Potential for cure by stage across the cancer spectrum in the United States","volume":"33","author":"Hubbell","year":"2024","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(21)01234-4","article-title":"Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study","volume":"398","author":"Sun","year":"2021","journal-title":"Lancet"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2020.06.015","article-title":"A randomized, placebo-controlled trial of pembrolizumab plus chemotherapy in patients with metastatic squamous NSCLC: protocol-specified final analysis of KEYNOTE-407","volume":"15","author":"Paz-Ares","year":"2020","journal-title":"J Thorac Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(20)32531-9","article-title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial","volume":"396","author":"Cortes","year":"2020","journal-title":"Lancet"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2202809","article-title":"Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer","volume":"387","author":"Cortes","year":"2022","journal-title":"N Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1200\/jco.22.01989","article-title":"Pembrolizumab plus pemetrexed and platinum in nonsquamous non-small-cell lung cancer: 5-year outcomes from the phase 3 KEYNOTE-189 study","volume":"41","author":"Garassino","year":"2023","journal-title":"J Clin Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2023.06.006","article-title":"Pembrolizumab plus axitinib versus sunitinib as first-line treatment of advanced renal cell carcinoma: 43-month follow-up of the phase 3 KEYNOTE-426 study","volume":"84","author":"Plimack","year":"2023","journal-title":"Eur Urol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1056\/evidoa2200214","article-title":"Five-year analysis of adjuvant pembrolizumab or placebo in stage III melanoma","volume":"1","author":"Eggermont","year":"2022","journal-title":"N Engl J Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2106391","article-title":"Adjuvant pembrolizumab after nephrectomy in renal-cell carcinoma","author":"Choueiri","year":"2021","journal-title":"N Engl J Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1910549","article-title":"Pembrolizumab for early triple-negative breast cancer","volume":"382","author":"Schmid","year":"2020","journal-title":"New Engl J Med N Engl J Med"},{"key":"B16","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.4_suppl.LBA359","article-title":"Overall survival results from the phase 3 KEYNOTE-564 study of adjuvant pembrolizumab versus placebo for the treatment of clear cell renal cell carcinoma (ccRCC)","author":"Choueiri","year":"2024","journal-title":"Am Soc Clin Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2409932","article-title":"Overall survival with pembrolizumab in early-stage triple-negative breast cancer","author":"Schmid","year":"2024","journal-title":"N Engl J Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(24)01756-2","article-title":"Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"404","author":"Spicer","year":"2023","journal-title":"Lancet"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2020.08.207","article-title":"Cost effectiveness analysis of pembrolizumab in the treatment of adults with stage III melanoma and lymph node involvement who have undergone complete resection - the Greek setting","author":"Yfantopoulos","year":"2020","journal-title":"Value Health"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2023.09.937","article-title":"Cost-effectiveness analysis of pembrolizumab for the adjuvant treatment of patients with renal cell carcinoma who have undergone nephrectomy in Greece","author":"Yfantopoulos","year":"2023","journal-title":"Value Health"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2023.09.478","article-title":"Cost-effectiveness analysis of pembrolizumab plus chemotherapy as neoadjuvant therapy and continued as a single agent as adjuvant therapy for high-risk early-stage triple-negative breast cancer in Greece","author":"Yfantopoulos","year":"2023","journal-title":"Value In Health"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2023.09.636","article-title":"EE370 cost-effectiveness analysis of pembrolizumab as adjuvant treatment for resected stage IIB\/IIC melanoma in Greece","volume":"26","author":"Yfantopoulos","year":"2022","journal-title":"Value Health"},{"key":"B23","volume-title":"Transparency Committe Summary: Keytruda Tnbc","year":"2022"},{"key":"B24","volume-title":"Opinnion on Medicinal Product: Keytruda RCC","year":"2023"},{"key":"B25","volume-title":"Opinnion on Medicinal Product: Keytruda Melanoma","year":"2022"},{"key":"B26","volume-title":"[A22-71] Pembrolizumab (Renal Cell Carcinoma) \u2013 Benefit Assessment","year":"2023"},{"key":"B27","volume-title":"[A21-145] Pembrolizumab (Breast Cancer, Triple-Negative, Locally Recurrent\/Metastatic, in Combination With Chemotherapy) - Benefit Assessment","year":"2022"},{"key":"B28","volume-title":"[A22-72] Pembrolizumab (Melanoma, Adjuvant) \u2013 Benefit Assessment","year":"2022"},{"key":"B29","volume-title":"Agenzia Italiana Del Farmacodetermina: 20 Febbraio 2025","year":"2025"},{"key":"B30","volume-title":"Agenzia Italiana Del Farmacodetermina: 10 Luglio 2023","year":"2023"},{"key":"B31","volume-title":"Agenzia Italiana Del Farmacodetermina: 27 Novembre 2019","year":"2019"},{"key":"B32","unstructured":"Pembrolizumab for adjuvant treatment of completely resected stage 3 melanoma [TA766\n          \n          \n          \n          2022"},{"key":"B33","unstructured":"Pembrolizumab for adjuvant treatment of renal cell carcinoma [TA830\n          \n          \n          \n          2022"},{"key":"B34","unstructured":"Pembrolizumab for neoadjuvant and adjuvant treatment of triple-negative early or locally advanced breast cancer [TA851\n          \n          \n          \n          2022"},{"key":"B35","article-title":"Pembrolizumab for adjuvant treatment of resected stage 2B or 2C melanoma [TA837","year":"2022"},{"key":"B36","volume-title":"Greece Cancer Fact Sheet","year":"2022"},{"key":"B37","volume-title":"Greek Population Index","year":"2021"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-011184","article-title":"Clinical factors influencing retreatment with anti-PD-(L)1 therapies after treatment in early-stage cancers: a modified Delphi consensus study","volume":"13","author":"Pusztai","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B39","unstructured":"Study of pembrolizumab (MK-3475) versus placebo after complete resection of high-risk stage III melanoma (MK-3475-054, 1325-MG, KEYNOTE-054) clinicaltrials.gov[updated august 21, 2023"},{"key":"B40","unstructured":"Safety and Efficacy Study of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (MK-3475-564, KEYNOTE-564) clinicaltrials.gov[updated June 29, 2023"},{"key":"B41","unstructured":"Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522, KEYNOTE-522) Clinicaltrial.gov[updated July 3, 2023"},{"key":"B42","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-030-47622-9","article-title":"Methods for analysing and reporting EQ-5D data","volume-title":"Springer","author":"Devlin","year":"2020"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1007\/s10198-003-0182-5","article-title":"A single European currency for EQ-5D health states. Results from a six-country study","volume":"4","author":"Greiner","year":"2003","journal-title":"Eur J Health Econ"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4733.2010.00700.x","article-title":"Populating an economic model with health state utility values: moving toward better practice","volume":"13","author":"Ara","year":"2010","journal-title":"Value health: J Int Soc For Pharmacoeconomics Outcomes Res"},{"key":"B45","volume-title":"Goverment Gazzete 3918a31","year":"2011"},{"key":"B46","volume-title":"Price Bulletin","year":"2023"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2019.09.405","article-title":"End-of-life cost for lung cancer patients in Greece: a hospital-based retrospective study","author":"Kokkotou","year":"2021","journal-title":"J Comp Eff Res"},{"key":"B48","volume-title":"Greek Drg's Catalogue","year":"2019"},{"key":"B49","article-title":"Disease management and resource use for the management of melanoma stage IIIc or IV positive for BRAF V600 mutations in Greece","author":"Carayianni","year":"2021","journal-title":"Med Clin Res"},{"key":"B50","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s12962-022-00339-2","article-title":"Treatment pathways and associated costs of metastatic colorectal cancer in Greece","volume":"20","author":"Sougklakos","year":"2022","journal-title":"Cost Eff Resour Alloc"},{"key":"B51","volume-title":"Median Hourly Earnings","year":"2024"},{"key":"B52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/14796694.2024.2436342","article-title":"Impact of recurrence on employment, finances, and productivity for early-stage cancer patients and caregivers: US survey","author":"Aguiar-Ibanez","year":"2024","journal-title":"Future Oncol"},{"key":"B53","volume-title":"Therapeutic Protocolls EOPE 2024, 10th Edition","year":"2024"},{"key":"B54","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1001\/jamadermatol.2022.0160","article-title":"Global burden of cutaneous melanoma in 2020 and projections to 2040","volume":"158","author":"Arnold","year":"2022","journal-title":"JAMA Dermatol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14051253","article-title":"Triple negative breast cancer: Updates on classification and treatment in 2021","volume":"14","author":"Bou Zerdan","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B56","article-title":"Improving the care of women with triple-negative breast cancer","volume":"2","year":"2023"},{"key":"B57","doi-asserted-by":"publisher","first-page":"37","DOI":"10.4236\/jct.2017.81004","article-title":"Patient and physician preferences for treating adjuvant melanoma: A discrete choice experiment","volume":"8","author":"Beusterien","year":"2017","journal-title":"J Cancer Ther"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1007\/s11764-013-0272-z","article-title":"Fear of cancer recurrence in adult cancer survivors: a systematic review of quantitative studies","volume":"7","author":"Simard","year":"2013","journal-title":"J Cancer Surviv"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejcskn.2023.100014","article-title":"Adjuvant immune checkpoint blockade revisited; the need to consider more factors and involve all stakeholders","volume":"2","author":"van Akkooi","year":"2024","journal-title":"EJC Skin Cancer"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/j.iotech.2025.101042","article-title":"Challenges and opportunities of predicting overall survival benefit from improvements to recurrence- free survival in stage II\/III melanoma: a correlation meta-analysis","volume":"25","author":"Leung","year":"2025","journal-title":"Immuno-Oncology Technol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2021.39.15_suppl.4581","article-title":"Disease-free survival as a predictor of overall survival in localized renal cell carcinoma (RCC) following first nephrectomy","author":"Haas","year":"2021","journal-title":"Wolters Kluwer Health"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtcvs.2023.12.006","article-title":"Event-free survival as a predictor of overall survival and recurrence burden of patients with non-small cell lung cancer receiving neoadjuvant therapy","author":"Donington","year":"2023","journal-title":"J Thorac Cardiovasc Surg"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2023-0315","article-title":"Association between event-free survival and overall survival in early-stage triple-negative breast cancer","volume":"20","author":"Huang","year":"2024","journal-title":"Future Oncol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1007\/s40487-025-00357-z","article-title":"The health impact of using anti-PD-1 agents to treat early-stage cancer in Belgium","volume":"13","author":"Bento-Abreu","year":"2025","journal-title":"Oncol Ther"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1601377","article-title":"Health impact of using anti-PD-(L)1 agents to treat early-stage cancers in Switzerland: a modeling study","volume":"16","author":"Favre-Bulle","year":"2025","journal-title":"Front Immunol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1613120","article-title":"Impact on health outcomes and productive work of adding anti-PD-1 agents to treat early-stage cancers in the United Kingdom: a modelling study","volume":"16","author":"Burton","year":"2025","journal-title":"Front Pharmacol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2024.10.090","article-title":"Impact on health outcomes and productive work of anti-PD-(L)1 inhibitors to treat early-stage cancers in scotland(EF23)","author":"Burton","year":"2024"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1080\/14737167.2026.2634755","article-title":"Impact of early-stage immunotherapy on health and work productivity in the Czech Republic, 2024-2033","volume":"26","author":"Blezer","year":"2026","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2026.2626240","article-title":"Health and productivity benefits of anti-PD-(L)1 agents for early-stage cancer treatment in Hungary","volume":"29","author":"Ladino","year":"2026","journal-title":"J Med Econ"},{"key":"B70","article-title":"Keytruda for the adjuvant treatment of Stage IIB\/IIC or Stage III melanoma","year":"2022"},{"key":"B71","article-title":"Keytruda assessement for perioperative Tripple Negative Breast Cancer","year":"2022"},{"key":"B72","article-title":"Keytruda for adjuvant treatment of high risk Renal Cell Carcinoma patients","year":"2021"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1814460\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T09:51:00Z","timestamp":1787133060000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1814460\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,19]]},"references-count":72,"alternative-id":["10.3389\/fonc.2026.1814460"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1814460","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,19]]},"article-number":"1814460"}}